title: Are novel serum biomarkers informative?
abstract: To justify use in routine coronary heart disease (CHD) risk assessment, a novel serum biomarker must be specifically associated with future CHD events and add information beyond techniques currently available. Current risk assessment techniques are probabilistic and imperfect; however, to date, no novel serum biomarker has improved substantially on the current population-based risk stratification approach. Although limited trial-based data are available to assess the utility of biomarkers, insights gained from biomarkers may enhance clinical decision making. Continued basic science and population-based research into CHD biomarkers may help to further the capacity for CHD risk assessment.
authors.affiliation: Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
authors.forename: John T
authors.initials: JT
authors.lastname: Wilkins
authors.forename: Donald M
authors.initials: DM
authors.lastname: Lloyd-Jones
mesh_terms: D053299:Apolipoprotein B-100 / Q000097:blood*; D015415:Biomarkers / Q000378:metabolism; D002097:C-Reactive Protein / Q000378:metabolism*; D003327:Coronary Disease / Q000097:blood / Q000453:epidemiology / Q000517:prevention & control; D019468:Disease Management; D006801:Humans; D017270:Lipoprotein(a) / Q000097:blood*; D015233:Models, Statistical; D012372:ROC Curve; D018570:Risk Assessment / Q000379:methods / Q000706:statistics & numerical data; D012307:Risk Factors; D055502:Secondary Prevention; D019210:Troponin I / Q000097:blood*
chemical_list: D053299:Apolipoprotein B-100; D015415:Biomarkers; D017270:Lipoprotein(a); D019210:Troponin I; D002097:C-Reactive Protein